| RSLS Stock | | | USD 5.68 0.07 1.22% |
Chairman
Mr. Dan W. Gladney is Chairman of the Board of the Company. He is no longer President, Chief Executive Officer of the Company effective as of March 31, 2019. Mr. Gladney has served as our President and Chief Executive Officer since November 16, 2015 and as Chairman of our board of directors since October 14, 2016. Mr. Gladney joined the Company on November 2, 2015 as PresidentElect and a member of the board of directors. Prior to joining us, Mr. Gladney served as Chairman and Chief Executive Officer of Lanx, Inc., a medical device company focused on developing and commercializing innovative devices for spinal surgery. Prior to his time at Lanx, Inc., Mr. Gladney was a Healthcare Operating Partner at Norwest Equity Partners from 2008 until 2010, where he was responsible for strategic planning, business growth and corporate governance for NEP portfolio companies and executing new investment opportunities for the firm. Prior to joining NEP, Mr. Gladney served as President and Chief Executive Officer of several medical device companies including Heart Leaflet Technologies and ACIST Medical Systems, both of which were acquired by The Bracco Group. He also served as Chairman, Chief Executive Officer and President of Complex Technologies, a publicly traded orthopedic and health and wellness electro therapy company, from 2002 until 2006. Mr. Gladney currently serves on the board of directors of ARIA CV, Inc. and was a member of a number of other private and public company boards. After the sale of Lanx, he acted as a private investor and small business consultant. since 2019.
| Age | 71 |
| Tenure | 5 years |
| Address | 18 Technology Drive, Irvine, CA, United States, 92618 |
| Phone | 949-429-6680 |
| Web | https://www.reshapelifesciences.com |
ReShape Lifesciences Management Efficiency
The company has return on total asset
(ROA) of
(0.6346) % which means that it has lost $0.6346 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.8459) %, meaning that it created substantial loss on money invested by shareholders. ReShape Lifesciences' management efficiency ratios could be used to measure how well ReShape Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -1.12 in 2024.
Return On Capital Employed is likely to drop to -2.23 in 2024. At this time, ReShape Lifesciences'
Total Current Assets are comparatively stable compared to the past year.
Net Tangible Assets is likely to gain to about 4
M in 2024, whereas
Other Assets are likely to drop slightly above 111.4
K in 2024.
ReShape Lifesciences currently holds 262
K in liabilities with Debt to Equity
(D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. ReShape Lifesciences has a current ratio of 2.08, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about ReShape Lifesciences' use of debt, we should always consider it together with its cash and equity.
Similar Executives
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. Reshape Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 47 people. ReShape Lifesciences (RSLS) is traded on NASDAQ Exchange in USA. It is located in 18 Technology Drive, Irvine, CA, United States, 92618 and employs 29 people. ReShape Lifesciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification.
Management Performance
ReShape Lifesciences Leadership Team
Elected by the shareholders, the ReShape Lifesciences' board of directors comprises two types of representatives: ReShape Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ReShape. The board's role is to monitor ReShape Lifesciences' management team and ensure that shareholders' interests are well served. ReShape Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ReShape Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Al Diaz, Vice RD | |
| DVM DVM, VP Officer | |
| Thomas Stankovich, Chief Officer | |
| MBA DVM, VP Officer | |
| Dan Gladney, Chairman of the Board and Presidentident, CEO | |
| Jody Dahlman, Director Communications | |
| Katherine Tweden, CoFounder | |
| Paul Hickey, Senior Vice President - Marketing and Reimbursement | |
| Mark Knudson, CoFounder CEO | |
| Naqeeb Ansari, Senior Vice President - Sales | |
ReShape Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ReShape Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to
measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to
predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.